Takeda faces challenging outlook as patent woes loom
This article was originally published in Scrip
Takeda saw solid profit gains in the fiscal year to 31 March on the absence of one-off costs related to its acquisition of Millennium. But stripping these out revealed underlying weakness, and the Japanese company is expecting a challenging few years as patents for its top product begin to expire.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.